2,2,2-trichloro-1-(4-(2-fluoro-4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone | 888721-22-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2,2-trichloro-1-(4-(2-fluoro-4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone
• 英文别名: 2,2,2-trichloro-1-[4-(2-fluoro-4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyridin-3-yl]ethanone
• CAS: 888721-22-0
• 化学式: C₁₅H₇Cl₃FN₃O₄
• 分子量: 418.596
• InChiKey: XIELDRWHNKLKII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,2,2-trichloro-1-(4-(2-fluoro-4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone 在 氯化铵 、 锌 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-[4-(4-amino-2-fluorophenoxy)-1H-pyrrolo[2,3-b]pyridin-3-yl]-2,2,2-trichloroethanone
  参考文献：
  名称：

  Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors

  摘要：

  A series of acylurea analogs derived from pyrrolopyridine and aminopyridine scaffolds were identified as potent inhibitors of Met kinase activity. The SAR at various positions of the two kinase scaffolds was investigated. These studies led to the discovery of compounds 3b and 20b, which demonstrated favorable pharmacokinetic properties in mice and significant antitumor activity in a human gastric carcinoma xenograft model.

  DOI：

  10.1016/j.bmcl.2008.04.047
• 作为产物：
  描述：

  4-(2-fluoro-4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyridine 、 三氯乙酰氯 在 aluminum (III) chloride 作用下， 以 1,2-二氯乙烷 为溶剂， 以76%的产率得到2,2,2-trichloro-1-(4-(2-fluoro-4-nitrophenoxy)-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone
  参考文献：
  名称：

  Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors

  摘要：

  A series of acylurea analogs derived from pyrrolopyridine and aminopyridine scaffolds were identified as potent inhibitors of Met kinase activity. The SAR at various positions of the two kinase scaffolds was investigated. These studies led to the discovery of compounds 3b and 20b, which demonstrated favorable pharmacokinetic properties in mice and significant antitumor activity in a human gastric carcinoma xenograft model.

  DOI：

  10.1016/j.bmcl.2008.04.047

文献信息

• Fused heterocyclic kinase inhibitors
  申请人：Borzilleri M. Robert

  公开号：US20050288290A1

  公开（公告）日：2005-12-29

  In general, the instant invention comprises compounds of Formulas I and II including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.

  一般而言，本发明涉及公式I和II的化合物，包括其药学上可接受的盐。本发明的化合物可用作蛋白激酶抑制剂，因此可用于治疗癌症和其他蛋白激酶介导的疾病。
• Pyrrolotriazine kinase inhibitors
  申请人：Borzilleri Robert M.

  公开号：US20060004006A1

  公开（公告）日：2006-01-05

  In general, the instant invention comprises compounds of Formulas I and II including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.

  一般而言，本发明涉及公式I和II的化合物及其药学上可接受的盐。本发明的化合物可用作蛋白激酶抑制剂，因此可用于治疗癌症和其他蛋白激酶介导的疾病。
• PYRROLOTRIAZINE KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1761268A2

  公开（公告）日：2007-03-14
• EP1761268A4
  申请人：——

  公开号：EP1761268A4

  公开（公告）日：2009-07-08
• US7173031B2
  申请人：——

  公开号：US7173031B2

  公开（公告）日：2007-02-06